Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Community Health Network

Neither a doctor nor a teaching hospital

Research payments

$1,509,890

83 payments

Through program year 2025, Community Health Network is reported as receiving $1,509,890 in research payments, across 83 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $21,319 6
2024 Research $14,824 3
2023 Research $1,281,082 56
2022 Research $192,314 16
2020 Research $210 1
2019 Research $140 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Seattle Genetics, Inc. $1,012,215 58 payments
  2. Pfizer Inc. $445,956 11 payments
  3. GlaxoSmithKline, LLC. $19,362 4 payments
  4. Amgen Inc. $14,460 4 payments
  5. Taiho Oncology, Inc. $13,321 1 payment
  6. Eli Lilly and Company $4,575 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. Open-Label Phase 1 Study of SGN-B7H4V for Solid Tumors $642,782 8 payments
  2. A Phase 1 Openlabel Multicenter Dosefinding Pharmacokinetic Safety and Tolerability Study of Pf07265807 in Participants With Selected Advanced Or Metastatic Solid Tumor Malignancies $445,758 10 payments
  3. An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies $328,447 47 payments
  4. Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors $40,986 3 payments
  5. A Phase 3A, Open-Label, Randomized, Controlled Study to Evaluate the I $19,362 4 payments
  6. A Phase 1 FIH PRMT5i therapy for treatment of MTAP null NSCLS $14,110 2 payments
  7. Phase 1 Study of TAS0612 $13,321 1 payment
  8. Sunray-01 A Global Pivotal Study in Participants With Kras G12c-Mutant Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Comparing First Line Treatment of Ly3537982 and Pembrolizumab VS Placebo and Pembrolizumab in Those With PD L1 Expression 50% Or Ly3537982 and Pembrolizumab Pemetrexed Platinum VS Placebo and Pembrolizumab Pemetrexed Platinum Regardless of Pd-L1 Expression $3,383 2 payments
  9. A Phase 1A/1B Study of Ly3484356 Administered As Monotherapy and in Combination With Abemaciclib to Patients With Er+, Her2- Locally Advanced Or Metastatic Breast Cancer $1,115 1 payment
  10. Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure (METEORIC-HF) $350 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record